Company Overview and News

 
An evening walk down Dalal Street | Sensex fails to hold 38,000, Nifty posts record close

2018-08-17 moneycontrol
The market ended a truncated week on a good note, as benchmark indices closed with strong gains. The Nifty ended the day at a record closing high, while the Sensex ended higher by almost 300 points. Having said that, it failed to hold 38,000-mark.
HINDALCO SAUKF 533262 VEDL SAUA AKLD HNDNF SAUD SAIL 500470 RAMKY TTST TATASTEEL TATLY IONEXCHANG 500113 500477 500214 ASTRAZEN 506820 AKLS 500440 ASHOKLEY

 
Ion Exchange locked in upper circuit after it wins Rs 438 cr order from Cairn

2018-08-17 moneycontrol
Ion Exchange hit the upper circuit in opening trade on Friday after the company reported that it has signed a contract for engineering, procurement, supply and construction of water treatment plant worth Rs 438.84 crore.
IONEXCHANG 500214

 
₹439-cr order may add strength to Ion Exchange

2018-08-17 thehindubusinessline
Ion Exchange (India) has signed a contract for engineering, procurement, supply and construction of water treatment plant worth ₹438.84 crore.
KMBKY KOTAKBANK IONEXCHANG 500247 500214

 
Launch of Test Work and Drilling Program

2018-08-13 accesswire
KELOWNA, BC / ACCESSWIRE / August 13, 2018 / Enertopia Corporation (OTCQB: ENRT) on the OTCQB and (CSE: TOP) on the CSE (the "Company" or "Enertopia") is pleased to announce the start of the second phase of bench-scale test work on lithium bearing clays from Clayton Valley, NV. The first phase has established that a synthetic brine high in lithium and low in magnesium can be produced by leaching at an elevated pH.
ENRT IONEXCHANG TOP 500214

 
Innovative Lithium Extraction Technique, Summary of Testing

2018-06-11 accesswire
KELOWNA, BC / ACCESSWIRE / June 11, 2018 / Enertopia Corporation (ENRT) on the OTCQB and (TOP) on the CSE, (OTCQB: ENRT) (CSE: TOP) (the "Company" or "Enertopia") is pleased to announce the following synthetic lithium brine testing update for the recovery of Lithium compounds by our technology partner, Genesis Water Technologies Inc. (GWT), a leader in specialized water treatment solutions.
ENRT IONEXCHANG TOP 500214

 
Dozen municipalities evinced interest in waste to energy plant: Ion Exchange

2018-03-29 economictimes.indiatimes
Copyright © 2018 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service
IONEXCHANG 500214

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...